What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia

Clinical Pharmacokinetics

Volumn 42, Issue 7, 2003, Pages 607-618

  Schulte, Peter F J ^a  

^a Mental Health Services North Holland North   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUVOXAMINE; HALOPERIDOL;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; CONVULSION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MONITORING; EPILEPSY; FOLLOW UP; HUMAN; MENTAL PATIENT; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; TIME; TITRIMETRY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE; HUMANS; SCHIZOPHRENIA; TIME FACTORS;

EID: 0043205845     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342070-00001     Document Type: Review

References (77)

1. Schulte PFJ. The place of clozapine in the treatment of schizophrenia. Tijdschrift voor Psychiatrie 2001; 43: 715-20
2. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-26
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 489-96
4. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 1997; 32: 93-100
5. Olesen OV. Therapeutic drug monitoring of clozapine treatment: therapeutic threshold value for serum clozapine concentrations. Clin Pharmacokin 1998; 34: 497-502
6. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for the therapeutic and adverse effects. J Clin Psychiatry 1994; 55 Suppl. 3: 78-81
7. Adomeit A, Rao ML, Rohde A, et al. Serumspiegelü-berwachung bei Therapie mit Clozapin. Psychopharmakotherapie 1995; 2: 81-3
8. Kurz M, Hummer M, Kemmler G, et al. Long-term pharmacokinetics of clozapine. Br J Psychiatry 1998; 173: 341-4
9. Kurz M, Hummer M, Kurzthaler I, et al. Efficacy of medium-dose clozapine for treatment-resistant schizophrenia. Am J Psychiatry 1995; 152: 1690-1
10. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenia. Am J Psychiatry 1991; 148: 231-5
11. Hasegawa M, Gutierrez-Esteinou R, Way L, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13: 383-90
12. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiatry 1994; 55 (9 Suppl. b): 133-6
13. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152: 179-82
14. Pickar D, Owen R, Litman R, et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345-53
15. Liu HC, Chang WH, Wei FC, et al. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996; 18: 200-7
16. Spina E, Avenoso A, Facciolá G. et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148: 83-9
17. La Pia S, Fabrazzo M, Bencivenga R, et al. Clozapine plasma levels and time to clinical response in a standardized trial. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: 307-8
18. Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? Neuropsychopharmacology 2002; 27: 1050-5
19. Chen YY, Jhao J, Xie G, et al. A study on serum concentration and clinical response to clozapine with different dose administration for teatment of schizophrenia. Chinese Journal of Psychiatry 1998; 31 (2): 104-7
20. Gu NF. Pharmacokinetic study of clozapine. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1988; 21: 259-62
21. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-resistant schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-84
22. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55 (9 Suppl. b): 117-21
23. Ciapparelli A, Dell'Osso L, Pini S, et al. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000; 61: 329-34
24. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry 1994; 55 Suppl. B: 126-8
25. Cooper TB. Clozapine plasma level monitoring: current status. Psychiatric Quarterly 1996; 67: 297-311
26. Kaladjian A, Bery B, Deturmeny E, et al. Clozapine monitoring: plasma or serum levels? Ther Drug Monit 1999; 21: 327-9
27. Perry PJ. Therapeutic drug monitoring of atypical antipsychotics. Is it of potential clinical value? CNS Drugs 2000; 13: 167-71
28. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994; 55 Suppl. B: 94-7
29. Frazier JA, Glassner Cohen L, Jacobson L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 2003; 23: 87-91
30. Gaertner I, Gaertner HJ, Vontheim R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 2001; 21: 305-10
31. Ulrich S, Baumann B, Wolf R, et al. Therapeutic drug monitoring of clozapine and relapse: a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41 (1): 3-13
32. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001; 62 Suppl. 5: 14-7
33. Oleson O, Thomsen K, Jensen P, et al. Clozapine serum levels and side-effects during steady-state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 1995; 117: 371-8
34. Simpson G, Cooper T. Clozapine plasma-levels and convulsion. Am J Psychiatry 1978; 135: 99-100
35. Haring C, Meise U, Barnas SC, et al. Dose related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989; 7: 347-51
36. Choc M, Lehr R, Hsuan F, et al. Multiple dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4: 402-5
37. Oyewumi L, Freeman D, Vollick D. Can low-dose clozapine pharmacokinetics predict steady-state plasma-concentration? Ther Drug Monit 1995; 17: 137-41
38. Lam YWF, Ereshefsky L, Toney GB, et al. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001; 62 Suppl. 5: 18-22
39. Van der Molen-Eijgenraam M, Blanken-Meijs JTHM, Heeringa M, et al. Delirium due to rise of clozapine levels during an inflammatory reaction. Ned Tijdschr Geneesk 2001; 145: 427-30
40. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171: 109-12
41. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-46
42. Dailly E, Urien S, Chanut E, et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (4): 699-703
43. Jerling M, Lindstörm L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74
44. Gabbay V, O'Dowd MA, Mamamtavrishvili M, et al. Clozapine and oral contraceptives: a possible drug interaction [letter]. J Clin Psychopharmacol 2002; 22: 621-22
45. Balogh A, Klinger G, Henschel L, et al. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 1995; 48: 161-66
46. Spina E, Avenoso A, Facciola G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 3: 141-5
47. Centorrino F, Baldessarini R, Kando J, et al. Serum concentration of clozapine and major metabolites: effects of cotreatment with valproate or fluoxetine. Am J Psychiatry 1994; 151: 123-5
48. Centorrino F, Baldessarini R, Frankenburg F, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153: 820-2
49. Khan AY, Preskom SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. J Clin Psychiatry 2001; 62: 375-6
50. Taylor D, Ellison Z, Ementon Shaw L. et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998; 13: 19-21
51. Eggert A, Crismon ML, Dorson PG. Lack of effect of fluoxetine on plasma-clozapine concentrations. J Clin Psychiatry 1994; 55: 454-5
52. Wetzel H, Anghelescu I, Szegedi A. et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18: 2-9
53. Chang W, Augustin B, Lane H. et al. In-vitro and in-vivo evaluation of the drug-drug interactions between fluvoxamine and clozapine. Psychopharmacology (Berl) 1999; 145: 91-8
54. Hiemke C, Weigmann H, Härtner S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-81
55. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990; 40: 722-47
56. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999; 32: 148-53
57. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000; 61: 594-9
58. Weigmann H, Müller H, Dahmen N, et al. Interactions of fluvoxamine with the metabolism of clozapine. Pharmacopsychiatry 1993; 26: 209
59. Lammers C, Deuschle M, Weigmann H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients: clinical experience. Pharmacopsychiatry 1999; 32: 76-7
60. Dequardo J, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996; 153: 840-1
61. Bender S, Eap C. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 1998; 55: 1048-149
62. Fabrazzo M, La Pia S, Monteleone P, et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 2000; 20: 708-10
63. Stern R, Kahn R, Davidson M, et al. Early response to clozapine in schizophrenia. Am J Psychiatry 1994; 151: 1817-8
64. Wilson W. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 1996; 153: 951-2
65. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-7
66. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 1145-9
67. Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998; 59 Suppl. 3: 44-8
68. Advokat CD, Bertram LJ, Comaty JE. Clinical outcome to clozapine treatment in chronic psychiatric inpatients. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 1-14
69. Conley R, Carpenter W, Tamminga C. Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154: 1243-7
70. Rosenheck R, Evans D, Herz L, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 1999; 25: 709-19
71. Rosenheck R, Dunn L, Peszke M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999; 156: 88-93
72. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717-25
73. Fabrazzo M, Esposito G, Fusco R, et al. Effect of treatment duration on plasma levels of clozapine and N-desmethyl-clozapine in men and women. Psychopharmacology 1996; 124: 197-200
74. Trappler B, Kwong V, Leeman C. Therapeutic effect of clozapine at an unusually high plasma level. Am J Psychiatry 1996; 153: 133-4
75. Trappler B, Kwong V, Leeman C. Therapeutic effect of clozapine at an unusually high plasma level. Am J Psychiatry 1996; 153: 133-4
76. Nordin C, Alme B, Bondesson U. CSF and plasma concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacology 1995; 122: 104-7
77. Shiloh R, Zemishlansky Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. Br J Psychiatry 1997; 171: 569-73